Hansoh Pharma

Historical price data

Hansoh Pharma's mission is to develop and deliver innovative, high-quality medicines that address significant unmet medical needs in China and worldwide. The company has achieved a dominant position as one of China's most valuable pharmaceutical entities, built upon the commercial success of flagship products and a rich pipeline of novel candidates. Its strategy leverages a fully integrated platform from discovery to commercialization, with a sharp focus on oncology and CNS disorders, while actively pursuing strategic global partnerships to expand its international footprint. Hansoh's substantial R&D investment and manufacturing scale underpin its ambition to become a global biopharmaceutical leader.

A fully integrated platform spanning small molecule and biologic drug discovery (including ADC technology), novel drug delivery systems, precision medicine biomarkers, and GMP manufacturing for both modalities.

Hansoh competes domestically with other Chinese biopharma leaders like Hengrui and BeiGene, and globally with multinational giants, particularly in oncology. Its integrated model and deep pipeline provide competitive advantages, but differentiation in crowded therapeutic classes remains a constant challenge.